AVXL
Anavex Life Sciences Corp.
NASDAQ · Healthcare · Biotechnology · US
$2.86
+0.35%Aug 25, 2026, 16:14 UTC
Anavex Life Sciences announced regulatory progress for its lead drug blarcamesine in Q3 2026.
Source:Aug 25, 2026, 00:00 UTC
Anavex Life Sciences Corp. reported a net income of $7.8 million for Q3 2026, compared with a net loss of $13.2 million in Q3 2025, with diluted EPS of $0.08.